艾伯维（ABBV.N）周五在第三季度业绩超出华尔街预期后，上调了全年利润预期。随着较新的免疫学药物销售激增，弥补了曾经的畅销药修美乐销售下滑的缺口。
AbbVie (ABBV.N) raised its annual profit forecast after topping Wall Street expectations for the third quarter on Friday, as booming sales of newer immunology drugs made up for the decline in former top-selling treatment Humira.
在Skyrizi和Rinvoq的带动下，艾伯维的免疫学产品线正在为这家药企填补前拳头药物修美乐留下的空白。修美乐是一种关节炎治疗药物，于2023年失去了美国专利独占权。
AbbVie's immunology franchise, led by Skyrizi and Rinvoq, is doing the heavy lifting for the drugmaker to fill the void left by its former marquee drug Humira, after the arthritis treatment lost US patent exclusivity in 2023.
根据LSEG汇编的数据，适应症涵盖皮肤和胃肠道疾病的Skyrizi本季度销售额达57.8亿美元，同比增长22.7%，超过了华尔街57.5亿美元的预期。
Skyrizi, indicated for skin and gastrointestinal conditions, recorded sales of $5.78 billion for the quarter, growing 22.7% from a year earlier and beating Wall Street estimates of $5.75 billion, according to data compiled by LSEG.
用于治疗多种炎症性关节、皮肤和胃肠道疾病的Rinvoq创造了27.1亿美元的收入，同比增长近24%。
Rinvoq, which is used to treat a range of inflammatory joint, skin and gastrointestinal conditions, generated $2.71 billion in revenue, up nearly 24% year over year.
艾伯维正依靠收购来延长其超越修美乐的增长跑道，并帮助抵消未来的专利到期风险。
AbbVie is leaning on acquisitions to extend its growth runway beyond Humira and help offset future patent expirations.
其于6月斥资109亿美元收购Apogee Therapeutics，为艾伯维的长期管线增加了实验性湿疹和哮喘治疗药物，尽管预计该交易将在2027年前拖累利润，直到2032年开始对盈利做出贡献。
Its $10.9 billion acquisition of Apogee Therapeutics in June adds experimental eczema and asthma treatments to AbbVie's long-term pipeline, though the deal is expected to dent profit through 2027 before contributing to earnings in 2032.
艾伯维的神经科学产品组合也助力业绩超预期，收入攀升19%至33.9亿美元，得益于Botox Therapeutic和抗精神病药Vraylar。
AbbVie's neuroscience portfolio also helped with the earnings beat, with revenue climbing 19% to $3.39 billion, helped by Botox Therapeutic and antipsychotic drug Vraylar.
该药企现在预计全年调整后每股利润为13.95美元至13.99美元，高于此前13.76美元至13.96美元的预期。该预期包含截至第三季度已计入的收购在研研发费用和里程碑费用带来的每股69美分冲击。季度营收为174亿美元，高于分析师预期的173.1亿美元。
The drugmaker now expects annual adjusted profit of $13.95 to $13.99 per share, compared with its prior view of $13.76 to $13.96. The forecast includes a 69 cents hit from acquired in-process R&D and milestone expenses booked year to date through the third quarter. Quarterly revenue came in at $17.40 billion, compared with analysts' estimate of $17.31 billion.
公司本季度调整后每股盈利为3.82美元，高于分析师预期的3.75美元。
The company earned an adjusted profit of $3.82 per share in the quarter, above analysts' expectations of $3.75.
艾伯维股价今年以来已上涨约27%，周四收于290.79美元的历史新高。
AbbVie shares have risen about 27% so far this year and closed at a record high of $290.79 on Thursday.